ASH 2021 sees Novartis launch a 'next-generation' CAR-T platform 14-Dec-2021 By Jane Byrne Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in its pipeline.
Adaptimmune in ‘vein-to-vein’ deal with Cryoport’s SmartPak 15-Oct-2019 By Vassia Barba Adaptimmune adopts Cryoport’s SmartPak logistic services for shipment of its oncology T-cell therapy candidates, under a three-year agreement.
‘A new frontier:’ US FDA approves Novartis’ $475,000 CAR-T cell cancer therapy 31-Aug-2017 By Dan Stanton Kymriah (tisagenlecleucel), made at the former-Dendreon site in New Jersey, has become the first gene modified cell therapy to be approved in the US.
Being for the $11.9bn benefit of investors of Kite: Gilead jumps into CAR-T 28-Aug-2017 By Dan Stanton Gilead will add a late-stage CAR T-cell candidate and a facility in California capable of treating 5,000 patients per year through the $11.9bn deal.